GRI Bio reports FY2023 net loss of $13.0M; cash runway extended into Q3 2024 after $5.5M offering

GRI Bio, Inc.

2024-Q1 EPS reported -$0.46

Net loss of $13.0M for FY2023; R&D expense $3.2M (up from $0.2M) and G&A $8.2M (up from $2.0M).
Cash and equivalents $1.8M as of Dec 31, 2023; subsequent Feb 2024 public offering raised $5.5M.
Phase 2a biomarker study for lead IPF drug GRI-0621 ongoing; interim data H1 2024, topline H2 2024.
GRI-0803 for SLE completing IND-enabling studies; IND filing on track for H1 2024.
Received notice of allowance for Canadian patent covering proprietary NKT cell modulators.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GRI Bio, Inc. reported financial results for fiscal year ended December 31, 2023.

Period: fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On April 1, 2024, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the year ended December 31, 2023, and provided a business update.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-24-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.